Human Papillomavirus Vaccines Market Size, Share & Industry Analysis, By Type (Preventive and Therapeutic), By Valency (Bivalent, Quadrivalent, and Nonvalent), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal & Vulvar Cancers, Genital Warts, and Others), By Gender (Male and Female), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

The global human papillomavirus vaccines market size was valued at USD 9.33 billion in 2024. The market is projected to grow from USD 9.67 billion in 2025 to USD 22.06 billion by 2032, exhibiting a CAGR of 12.50% during the forecast period. North america dominated the human papillomavirus vaccines market with a market share of 45.01% in 2024.

The rising prevalence of HPV-related cancer and diseases is expected to propel the demand and adoption of preventive measures available to reduce the burden on healthcare expenditure. The market is witnessing a noteworthy growth trajectory during the forecast period. Additionally, increasing awareness, school based vaccination programs, and strategies to boost the vaccination coverage for safeguarding the health are prominent factors towards propelling the market growth. Also, rise in the funding and investment activities to bolster the therapeutic vaccine development for safeguarding patients with HPV infection are expected to propel the global market development.

• For instance, in March 2024, as per the WHO, the global leaders announced the funding of USD 600 million at the Global Cervical Cancer Elimination Forum, Colombia, with the aim to propel the national and global momentum to end human papillomavirus (HPV) preventable disease.

Furthermore, the market encompasses several major players with Merck & Co. Inc. and GSK plc at the forefront. Robust product portfolio along with innovative strategies to expand the application area of the current vaccines is set to support the dominance of these companies in the global market.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Human Papillomavirus Infection to Propel the Market Growth

One of the most prominent driving factors of the market is the increasing prevalence of Human Papillomavirus (HPV) infection. The HPV infection is linked with various cancers such as cervical, vulvar, anal, oropharyngeal, and penile cancers, and genital warts. The spread of the vaccine is mostly due to sexual transmission from infected persons. Thus, to reduce the spread of HPV-related diseases, HPV vaccination programs act as a prominent preventive measure, contributing towards the global human papillomavirus vaccines market growth.

• For instance, in March 2024, as per the World Health Organization report, in 2022, globally cervical cancer was the fourth most common cancer in women with 6,60,000 new cases.

MARKET RESTRAINTS

Limited Accessibility of HPV Vaccines in the Emerging Countries to Restrict Market Growth

HPV is a vaccine-preventable infection, but limited coverage of vaccination in the lower economic regions increases the incidence of HPV related cancers. Such factors hamper the adoption of HPV vaccines and limit the market growth.

• For instance, in July 2025, as per the Global HPV Vaccination report published by The Centers for Disease Control and Prevention, more than 32.0 of the world’s countries, i.e., 64 out of 195, do not include HPV vaccination in their national immunization programs.
• Additionally, in April 2023, as per UNICEF in 2020, over 600,000 new cervical cancer cases, 340,000 deaths occurred in low and middle-income countries, and reported that around 90.0% of new cases occurred in low- and middle-income countries due to limited access to prevention, screening, and treatment services.

MARKET OPPORTUNITIES

Increasing Immunization Campaigns Worldwide to Create Lucrative Growth Opportunities

The increasing prevalence of vaccine preventable HPV associated cancer, and rising global economic burden of HPV related diseases have drawn significant attention. As a result, this has shifted the focus of government bodies to boost the vaccination campaigns.

• For instance, in November 2024, the Lao People's Democratic Republic Ministry of Health collaborated with UNICEF, the WHO, and Gavi to launch the HPV immunization campaign. The campaign aimed to vaccinate more than 124,000 girls aged 10 to 14 to help prevent cervical cancer. Such initiatives aimed to boost the global market demand and offer lucrative growth opportunities to the market.

MARKET CHALLENGES

Vaccine Hesitancy and Misinformation to Challenge the Market Growth

The impact of health literacy barriers leads to an increase in the circulation of misinformation regarding the HPV vaccines and thus challenges the market growth.

The fears about side effects and safety concerns, cultural beliefs, and traditional health practices may reduce the acceptance of preventive measures, thereby impeding market growth for HPV vaccines in the populations.

HUMAN PAPILLOMAVIRUS VACCINES MARKET TRENDS

Research and Development Activities to Launch Therapeutic Vaccines is a Prominent Market Trend

The current HPV vaccines are preventive types of vaccines, which do not treat or prevent the existing infection. Preventive vaccines are effective if only given in adolescent, thus leaving millions of infected adults without therapeutic options. Such factors have shifted the demand towards developing and launching therapeutic vaccines for the already infected patients.

• For instance, in January 2025, as per a journal of the American Association for Cancer Research presented a result from the phase II clinical trial reported that a therapeutic vaccine targeting human papillomavirus type 16 (HPV16) prompted deterioration of high-grade precancerous cervical lesions.

Download Free sample to learn more about this report.

Segmentation Analysis

By Type

Robust Presence of Preventive Vaccines to Propel Segmental Growth

On the basis of the segmentation of type, the market is classified into preventive and therapeutic.

The preventive vaccines segment accounted for a significant market share in 2024. The increasing prevalence of HPV associated cancer and spread due to limited awareness increases the demand for the adoption of preventive vaccination.

Also, currently, only preventive vaccines have been approved by the regulatory bodies, thus is expected to propel the segment’s growth. Furthermore, increasing approval and adoption of preventive vaccines by different regulatory authorities across the globe  is also set to propel the segment’s growth.

• For instance, in June 2025, Innovax Biotech Co., Ltd. received regulatory approval from China’s National Medical Products Administration (NMPA) for the 9-valent HPV vaccine, Cecolin 9.

To know how our report can help streamline your business, Speak to Analyst

By Valency

Increasing Demand and Development of Quadrivalent Vaccines to Bolster the Segment’s Growth

In terms of valency, the market is categorized into bivalent, quadrivalent, and nonvalent.

The quadrivalent segment held the maximum portion of the market and in 2025, the segment is anticipated to dominate with 28.5% share. The rising indigenous development of the quadrivalent HPV vaccine is bolstering the segment’s growth.

• For instance, in January 2023, Serum Institute of India Pvt. Ltd., in collaboration with Department of Biotechnology (DBT) and the Biotechnology Industry Research Assistance Council (BIRAC), developed and launched the first Quadrivalent Human Papillomavirus vaccine (qHPV) ‘CERVAVAC’ in India.

The nonvalent segment is expected to grow at a CAGR of 14.18% over the forecast period.  

By Disease Indication

Widespread Programs for Cervical Cancer Prevention to Supplement Segment Growth

Based on disease indication, the market is segmented into cervical cancer, anal cancer, vaginal & vulvar cancers, genital warts, and others.

The cervical cancer segment held the dominating position in 2024. By disease indication, the segment held the share of 61.8% in 2024. Rising number of cases of cervical cancer due to HPV infection in females is bolstering the demand for active immunization with available preventive vaccines. Additionally, key players and emerging players of the market are focusing on developing and launching new vaccines and government programs associated with cervical cancer prevention, which are collectively boosting the growth of the segment.

• For instance, in February 2025, Apollo Cancer Centres, in collaboration with CURE Foundation, launched a Free Cervical Cancer Vaccination Program. This program aimed to raise awareness and prevent cervical cancer.

The vaginal and vulvar cancer segment is set to flourish with a growth rate of 12.08% across the forecast period.

By Gender

Female Segment Takes the Lead Due to Presence of Active Immunization Programs

Based on gender, the market is divided into male and female.

The female segment held the maximum global human papillomavirus vaccines market share. The presence of active immunization programs for females is supporting the segment’s growth. This is due to the current immunization programs, which are gender specific and only target girls, assuming herd protection would shield boys.

• For instance, in June 2025, as per the study published by NIH, in 2023, 132 countries provided estimates for the first-dose coverage, while 129 countries reported coverage for the complete vaccination series. In this, the weighted average coverage among girls aged 9–14 years was 61.6% for the first dose and 47.6% for the full course.

The male segment is expected to grow with 15.95% CAGR across the forecast period.

By Distribution Channel

Active Government Strategies to Boost the Government Suppliers Segment Expansion

Based on distribution channel, the market is segmented into hospital & retail pharmacies, government suppliers, and others.

In 2024, the government suppliers segment held the largest market share. The rising focus of government bodies to increase accessibility and improve vaccination coverage to prevent HPV infections is propelling the segment’s growth. Furthermore, the segment is set to hold 48.5% share in 2025.

• For instance, in June 2025, during the Global Cervical Cancer Elimination Forum, Bali, world leaders announced a series of new investments and policy commitments to increase access to HPV vaccination, screening, and treatment.

In addition, the hospital & retail pharmacies distribution channel is projected to grow at a CAGR of 12.46% during the study period.

Human Papillomavirus Vaccines Market Regional Outlook

By geography, the market is categorized into Europe, North America, Asia Pacific, Latin America, and Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2023, valued at USD 4.23 billion, and also took the leading share in 2024 with USD 4.20 billion. North America’s dominance in the market is driven by factors such as a strong focus on preventing HPV infections, active government programs, and the presence of key players with strategic activities. In 2025, the U.S. market is estimated to reach USD 4.07 billion. The U.S. is expected to dominate the North America region owing to rising prevalence of HPV cases and presence of adequate vaccination programs offered by government to prevent the spread of the disease.

• For instance, in March 2024, Merck & Co. Inc. announced the plan to conduct a clinical trial for both females and males to evaluate the efficacy and safety of a single-dose regimen of GARDASIL 9 in comparison with a three-dose regimen.

Europe

Europe and the Asia Pacific, are anticipated to witness a notable growth in the coming years. During the forecast period, the European region is projected to record a growth rate of 10.79%, which is the second highest amongst all the regions, and touch the valuation of USD 2.21 billion in 2025. This is primarily driven by the increasing incidence of cancer and increasing human papillomavirus vaccines awareness program. Backed by these factors, countries including the U.K. are expected to record the valuation of USD 0.32 billion, Germany to record USD 0.59 billion, and France to record USD 0.48 billion in 2025.

Asia Pacific

After Europe, the market in the Asia Pacific is estimated to reach USD 2.63 billion in 2025 and secure the position of the third-largest region in the market. In the region, India and China are both estimated to reach USD 0.82 billion and 0.26 billion respectively in 2025.

Latin America and Middle East & Africa

Over the forecast period, the Latin America and Middle East & Africa regions would witness a moderate growth in the market. The Latin America market in 2025 is set to record USD 0.38 billion as its valuation. Rising government initiatives and focus on maintaining population health are bolstering the adoption of HPV vaccines. In the Middle East & Africa, GCC is set to attain the value of USD 0.01 billion in 2025.

COMPETITIVE LANDSCAPE

Key Industry Players

Expansion of Product Offering and Strong Research and Development Activities to Maintain Their Positions

The global human papillomavirus vaccines market shows a consolidated structure with a small number of large-sized companies actively operating across the globe. These players offer prominent HPV vaccine products across the globe with government support.

Merck & Co., Inc., and GSK plc are some of the dominating players in the market. The strong range of human papillomavirus vaccines, with strategic activities to expand their offerings for different HPV related cancers or lesions, is set to boost their positions in the market.

Apart from this, other prominent players in the market include Serum Institute of India Pvt. Ltd., THERAVECTYS, ViciniVax, Walvax Biotechnology Co., Ltd., among other are the major key players in the market. These key players are focusing on the development of therapeutic HPV vaccines with a significant focus on innovative product development to enhance their market presence.

LIST OF KEY HUMAN PAPILLOMAVIRUS VACCINES COMPANIES PROFILED

• GSK plc. (U.K.)
• Merck & Co., Inc. (U.S.)
• Serum Institute of India Pvt. Ltd. (India)
• THERAVECTYS (U.S.)
• ViciniVax (The Netherlands)
• Walvax Biotechnology Co., Ltd. (China)
• Xiamen Innovax Biotech CO., LTD. (China)

KEY INDUSTRY DEVELOPMENTS

• May 2025: Merck & Co. Inc. unveiled the new dosing regimens for GARDASIL 9. It is a 9-valent HPV vaccine used to prevent cancers and diseases associated with HPV.
• August 2024: Walvax Biotechnology Co., Ltd., received pre-qualification for Walrinvax from the World Health Organization (WHO). It is a HPV vaccine used for the treatment of cervical cancer.
• November 2023: TheraVectys announced the clearance for the initiation of phase 1 from the U.S. Food and Drug Administration for its therapeutic vaccine, Lenti-HPV-07, cervical cancer vaccine.
• June 2020- Merck & Co., Inc. received approval from the U.S.FDA for Gardasil9. A preventive vaccine for the human papillomavirus (HPV) associated head and neck cancers.
• May 2020: Innovax received the license for the use of Cecolin in China. It is a HPV vaccine used to treat cervical cancer in China.

REPORT COVERAGE

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation